Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
OGEN vs MTNB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
MTNB Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 4–1 Matrix Metrics)
MTNB Overall Winner
6-Pillar Tally: OGEN 1 – 2 MTNB (3 Tie)
Matrix Metrics: OGEN 1 – 4 MTNB
As of Nov 19, 2026, Matinas BioPharma Holdings, Inc. (MTNB) is the stronger overall head-to-head candidate over Oragenics Inc. (OGEN) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). OGEN carries a Unified Composite Score of 40.8/100 (SELL) at $0.17 (N/M Forward P/E, 0.0% operating margin), whereas MTNB carries 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin).
- Technical & Structure Timing Caution: OGEN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 15.6); meanwhile MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About OGEN vs MTNB
OGEN
Oragenics Inc.
$0.17
-8.99% 1D
Market Cap
$852,759
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.23β · 154% Vol
Unified Composite Score
40.8
SELL
Tech 30.0
Fund 50.0
Flow 50.0
Mom 75.0
Weinstein Technical Phase
Markdown · Sell / avoid
MTNB
Head-to-Head Winner
Matinas BioPharma Holdings, Inc.
$0.81
-10.98% 1D
Market Cap
$979,904
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
-7.20β · 147% Vol
Unified Composite Score
54.6
HOLD
Tech 53.0
Fund 58.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (OGEN 1 – 2 MTNB)
1. Valuation Multiples
Tie
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
N/M
2. Growth & Scale
OGEN
Revenue Growth (YoY)
-91.3%
-100.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
N/A
Market Cap
$852,759
$979,904
3. Profitability & Quality
MTNB
Gross Margin
N/A
N/A
Operating Margin
0.0%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-1307.1%
-147.5%
4. Balance Sheet & Cash Flow
MTNB
Cash Generation (TTM)
N/A
N/A
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$1.94 Book/Sh · -1307.1% ROE
$1.2M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: OGEN (1) vs MTNB (4)| Institutional Metric | OGEN | MTNB | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $852,759 | $979,904 | Tie | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -91.3% | -100.0% | OGEN | |
| Operating Margin (TTM) | 0.0% | 0.0% | Tie | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -1307.1% | -147.5% | MTNB | |
| 52-Week Range Position | 4% ($0–$1) | 22% ($0–$3) | MTNB | |
| Beta / 30D Volatility | 1.23β · 154% Vol | -7.20β · 147% Vol | MTNB | |
| Unified Institutional Score | 40.8 / 100 (SELL) | 54.6 / 100 (HOLD) | MTNB | |
| Trailing 12M Revenue (USD) | N/A | N/A | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | N/A ($1.94 Book/Sh · -1307.1% ROE) | N/A ($1.2M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
MTNB +11.63 pp
3M Horizon
MTNB +374.73 pp
6M Horizon
MTNB +91.78 pp
1Y Horizon
MTNB +52.76 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OGEN Revenue | MTNB Revenue | OGEN Op. Margin | MTNB Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2015 | N/A | $0M | N/A | -5096.0% | MTNB |
| FY2017 | N/A | $0M | N/A | -11024.6% | MTNB |
| FY2018 | N/A | $0M | N/A | -12230.9% | MTNB |
| FY2019 | N/A | $0M | N/A | -21067.4% | MTNB |
| FY2020 | N/A | $0M | N/A | -15288.4% | MTNB |
| FY2021 | $0M | $0M | -18130.3% | -74954.5% | OGEN |
| FY2022 | $0M | $0M | -10964.6% | -771.3% | MTNB |
| FY2023 | $0M | $0M | -55519.9% | -2168.4% | MTNB |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
OGEN
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact OGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
MTNB
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact MTNB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
OGEN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
MTNB Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ OGEN vs MTNB Key Questions & Quantitative Answers
As of Nov 19, 2026, Matinas BioPharma Holdings, Inc. (MTNB) is the stronger overall head-to-head candidate over Oragenics Inc. (OGEN) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). OGEN carries a Unified Composite Score of 40.8/100 (SELL) at $0.17 (N/M Forward P/E, 0.0% operating margin), whereas MTNB carries 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: OGEN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 15.6); meanwhile MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
OGEN leads the Growth & Scale pillar: OGEN posts -91.3% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MTNB at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2015 to FY2023), OGEN cumulative revenue shifted N/A while MTNB shifted N/A. In operating R&D and SG&A reinvestment, OGEN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MTNB.
OGEN and MTNB trade at balanced relative valuation multiples. OGEN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MTNB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OGEN (-1307.1% ROE) versus MTNB (-147.5% ROE) capital efficiency.
In options market volatility and institutional positioning, OGEN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.23β · 154% Vol realized risk). By comparison, MTNB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.20β · 147% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
MTNB vs OGEN · Reverse Pair
OGEN vs VTVT
· Sector Peer
MTNB vs VTVT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal